Traffic Lights - Latest Updates

Last updated: 05/09/2022

Other updates on this site
Drug Name Classification Clinical Indication Comments
ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena®) (UPDATED) Yellow Maintenance treatment of schizophrenia in patients currently stabilised on oral aripiprazole

See the LLR Antipsychotic Prescribing Guide 

2 strengths available: 400mg (each month) and 960mg (every 2 months)

Aspirin Yellow Chemoprevention for colorectal cancer for patients with Lynch Syndrome identified via Clinical Genetics

*on advice of clinical genetics

Patient weight <75kg: 150mg daily

Patient weight >75kg: 300mg daily

ATOMOXETINE (UPDATED) Orange Attention deficit hyperactivity disorder (ADHD)

Adults
Full SCA

Children and adolescents
Full SCA

 

BETULA VERRUCOSA ALLERGEN EXTRACT (Itulazax®) (NEW) Red Moderate to severe allergic rhinitis/conjunctivitis caused by Birch pollen

SCA Link Adult

SCA Link Paediatrics

Bismuth, Metronidazole & Tetracycline ( Pylera) (NEW) Green Eradication of H. Pylori for patients with penicillin allergy already exposed to clarithromycin

Use in line with local antimicrobial guidelines.

Denosumab (Xgeva) Red Prevention of skeletal related events for myeloma patients with CKD (GFR <10ml/min)
DERMATOPHAGOIDES PTERONYSSINUS ALLERGEN EXTRACT (Acarizax®) (UPDATED) Orange Immunotherapy treatment for house dust mite and allergic rhinitis in paediatrics.

SCA link Adult

SCA Link Paediatrics

DEXAMFETAMINE (UPDATED) Orange Attention deficit hyperactivity disorder (ADHD)

Adults
Full SCA

Children and adolescents
Full SCA

DexcomONE + Yellow Diabetes glucose monitoring for those included on the LLRAPC position statement

Update September 2024: DexcomONE + is now available; all new patients must be started on the updated device. DexcomONE is due to be discontinued early 2025, exact date to be confirmed.

Estradiol & Medroxyprogesterone (Tridestra) (NEW) Green Hormone replacement therapy
Estradiol & Norethisterone (Trisequens) (NEW) Green Hormone replacement therapy
ESTRADIOL HEMIHYDRATE/NORETHISTERONE ACETATE/RELUGOLIX (Ryeqo ®) (UPDATED) Yellow For treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

Treatment for 6-12 months at the direction of specialist team. In line with NICE TA832

classification or pathway

Finerenone Green Stage 3 and 4 chronic kidney disease associated with diabetes

For treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults in line with NICE TA877. Use in line with the CKD Pathway.

Freestyle Libre 2 Plus Yellow Continuous glucose monitoring (CGM) for those included on the LLRAPC position statement.

Update September 2024: Freestyle Libre 2 Plus is now available; all new patients must be started on the updated device. Freestyle Libre 2 is due to be discontinued early 2025, exact date to be confirmed.

GRASS POLLEN ALLERGEN EXTRACT sublingual (Grazax®) (UPDATED) Orange Grass pollen allergies

SCA Link Adult 

SCA Link Paediatrics

GUANFACINE (UPDATED) Orange ADHD - Adult

Adult Full SCA and Request Form

Lebrikizumab (NEW) Red For treating moderate to severe atopic dermatitis in people 12 years and over

TA986

LEFLUNOMIDE (UPDATED) Orange Rheumatological disease

Full SCA     Request form

LISDEXAMFETAMINE DIMESYLATE (UPDATED) Orange ADHD when response to methylphenidate is inadequate

Adults
Full SCA

Children and adolescents
Full SCA

METHOTREXATE Oral (UPDATED) Orange Rheumatological disease

 Full SCA            Request form

Always prescribe oral Methotrexate in multiples of 2.5mg tablet strength. The 10mg tablets must NOT be prescribed or supplied.

METHYLPHENIDATE (UPDATED) Orange Attention deficit hyperactivity disorder (ADHD)- prescribe CR formulation by brand name only

For information about products please see relevant Shared Care.
Adults:  Full SCA
Children & adolescents:  Full SCA

Nephrotrans (UPDATED) Yellow metabolic acidosis in chronic kidney disease

Treatment of metabolic acidosis and for maintenance treatment against recurrence of metabolic acidosis in adults with chronic renal impairment only (limited use as a 2nd line option for patients who cannot tolerate the standard capsules e.g. due to bloating).’ To be initiated by renal team only.

Tenecteplase (NEW) Red For treating acute ischaemic stroke

TA990

Varenicline Tartrate (Champix) Grey Smoking cessation in adults

Other Updates on this Website

Recent documents from LLR APC and TAS


About the Leicester, Leicestershire and Rutland Area Prescribing Committee

In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more